Therefore, we suggested that overexpression of MCM3AP-AS1 was closely related to patients' poor prognosis and CFS; MCM3AP-AS1 can be used as a diagnostic marker and therapeutic target for cancer patients and can predict poor prognosis. The gene discussed is MCM3AP; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.